In Ethiopia, the medicines with the biggest and steadiest demand are anti-infectives (antibiotics, antimalarials, antiretrovirals), Central Nervous System medicines, Intravenous fluid and electrolytes replacement agents and drugs that address gastrointestinal conditions. These jointly constitute the largest share of the health system’s budget (more than 80%). In terms of volume, oral solid dosage forms (capsules and tablets) constitute the greatest majority of sales across the sector.
Ethiopian generics exporters are in relatively small local competition for their product portfolios due to the fact that locally based production only satisfies approximately 90 out of the country’s list of 380+ essential medicines. Exporters specialising in oncology drugs, pediatric dosages and dialysers also have high demand to meet on an unmet basis, and enjoy minimal local competition.
Why This Matters for Exporters in 2026?
In fact, Ethiopia’s market size for pharmaceutical products has been growing at around 25% year-on-year for the last ten years, from $800-900 million dollars to a 2025 forecast of $1.8 billion and a 2030 projection of $3.6 billion. Even with such growth, 15-20% is the extent to which local drug supply satisfies total demand, with almost 80% of yearly demand for medicines met through imports. From a supplier’s perspective, not only is the Ethiopian market a growth opportunity, it is structurally import-dependent and faces a growing demand supply deficit, which is projected to be around USD 700 million in 2025.
The Four Categories that are Driving Demand
1. Anti-Infectives (Antibiotics, Antimalarials, Antiretrovirals)
The prevalence of diseases in Ethiopia, such as malaria, HIV, tuberculosis and various bacterial infections,s makes the use of anti-infectives the largest single therapeutic area by volume and value in the public sector. Although Local production has been identified by the Ethiopian Pharmaceutical Manufacturers’ plants program as the local production of antibiotics, antimalarials, and antiretrovirals as the priority, imports will likely dominate for newly developed and second-generation antibiotics, as well as for newer ARVs.
2. Central Nervous System (CNS) Medicines
Central Nervous System Drugs used for treating the central nervous system disorders and pain management, epilepsy and disorders of the psyche, represent the fourth leading medicine category by expenditures in the public health system, in addition to the above-mentioned three. Higher chronic disease prevalence,e as well as increased average life expectancy of the urban population, will result in a continued increase in annual demand for this category.
3. Fluid and Electrolyte Replacement Agents
For the treatment of the population in Ethiopia’s network of health care centres and hospitals, rehydration products and intravenous fluids are crucial since in the country there are numerous people still affected with diarrheal illnesses, and because of operational reasons, there is significant reliance on transportation of cold-chain-dependent medicines to remote areas.
4. Gastrointestinal
(GI) Medicines used for treating the gastrointestinal tract are the fourth leading category; the total expenditure made with the other three categories makes up over 80 per cent of public health sector expenditure in medicines.
High-Opportunity Niches to Invest
Oncology and Dialysis Medications: Voices from the Industry and others. Actors from the import businesses, which pioneered the importation of antiretrovirals two decades ago, are now of the opinion that, of all the medicines available in the market, cancer and dialysis medicines are the hardest to find in the local market, and talk about the rising, unfulfilled market demand for these medicines.
Pediatric Formulations: Multiple facility-level studies show the availability of children’s essential medicines to be low (in the range of 31.5% – 43%), showing a supply gap that can be filled by exporters of pediatric-specific dosage forms.
Chronic Disease (NCD) Medicines: As Ethiopia continues its process of urbanisation, the treatment of the non-communicable diseases of diabetes, hypertension and medicines of the cardiovascular system are expanding, though affordability and access to the private sector remain the major difficulties documented by WHO/HAI studies in Eastern Ethiopia.
Generic Medicines: Ethiopia’s public sector—making up nearly 75% of all medicines consumed in the country—procures based on price and generally opts for generics. With competitive prices, both generic manufacturers and exporters of medicines have a significant advantage in public tenders of the Ethiopian Pharmaceutical Supply Service (EPSS).
Where Imports Currently Come From?
India, the Netherlands, and Belgium are Ethiopia’s three leading source countries for finished pharmaceutical imports, with India alone supplying roughly a fifth of the market; China is also growing rapidly as an alternative source for both finished products and manufacturing equipment. This concentration means exporters from other regions — the Middle East, East Asia, or local African manufacturers — can differentiate through pricing, faster delivery, or product categories underserved by the dominant suppliers.
Practical Takeaways for Exporters
- The leading 4 therapeutic areas (anti-infectives, CNS, IV fluids, GI) should represent your biggest, most stable volume opportunity with EPSS tenders.
- Undeserved niche areas (oncology, dialysis and paediatrics) should form part of your offering – where there are higher margins and a lower level of competition.
- Have your strategy in place to serve both channels – fight price for EPSS tenders where it will inevitably be the lowest price; position based on brand and quality in the private pharmacy channel.
- Build compliance into your pitch – there are a large number of exporters who have the ability to leverage a fully traceabile supply chain hub and rapid EFDA registration times. History in this country shows a high risk of counterfeit products and stockouts in the major centres.
Frequently Asked Questions
What is the most important medicine category in Ethiopia?
Anti-infectives (antibiotics, antimalarials, antiretrovirals) lead in both volume and value, followed by CNS medicines, IV fluids/electrolytes, and GI drugs.
Why can’t Ethiopia produce more of its own medicine?
Local manufacturers can supply only 90 of the 380+ products on the national essential medicines list, limited by raw material imports, forex shortages, and a smaller manufacturing base that currently meets just 15–20% of national demand.
Is the public or private market bigger for pharma exporters?
The public sector consumes about 75% of all medicines in Ethiopia by volume (mostly generics via EPSS tenders), while about 90% of branded products are sold through the private market.
Which countries currently dominate Ethiopia’s pharmaceutical imports?
India, the Netherlands, and Belgium are the top three source countries, with China expanding its share.
